Detalles de la búsqueda
1.
Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
Pain Pract
; 17(2): 229-238, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26857424
2.
IV acetaminophen: Efficacy of a single dose for postoperative pain after hip arthroplasty: subset data analysis of 2 unpublished randomized clinical trials.
Am J Ther
; 22(1): 2-10, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-24413368
3.
Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives.
Therap Adv Gastroenterol
; 14: 17562848211032320, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34377150
4.
A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
J Pain Res
; 13: 605-612, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32280263
5.
Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
J Pain
; 8(2): 175-84, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17145204
6.
Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
J Opioid Manag
; 12(2): 139-47, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27194199
7.
Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
Pain Manag
; 6(5): 497-508, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27050830
8.
Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
J Pain
; 6(1): 21-8, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15629415
9.
Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: a randomized trial.
Curr Med Res Opin
; 21(9): 1485-93, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16197668
10.
Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain.
J Pain Res
; 8: 623-36, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26396543
11.
Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
J Opioid Manag
; 11(5): 425-34, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26535970
12.
Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
J Opioid Manag
; 11(6): 507-18, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26728648
13.
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.
Pain
; 156(9): 1660-1669, 2015 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25993547
14.
A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain.
J Pain Res
; 7: 669-78, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25473308
15.
Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
J Pain Res
; 6: 319-29, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23658495
16.
Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
J Pain Symptom Manage
; 44(6): 852-65, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22795050
17.
Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
J Opioid Manag
; 8(5): 299-314, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23247907
Resultados
1 -
17
de 17
1
Próxima >
>>